🇺🇸 FDA
Pipeline program

Zoledronic Acid

CZOL446K2418

Approved small_molecule completed

Quick answer

Zoledronic Acid for Paget's Disease of the Bone is a Approved program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Paget's Disease of the Bone
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials